December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
An In Vitro Comparison of 2nd, 3rd, and 4th Generation Fluoroquinolones Against Bacterial Keratitis Isolates
Author Affiliations & Notes
  • RP Kowalski
    The Charles T Campbell Laboratory University of Pittsburgh Pittsburgh PA
  • LM Karenchak
    The Charles T Campbell Laboratory University of Pittsburgh Pittsburgh PA
  • EG Romanowski
    The Charles T Campbell Laboratory University of Pittsburgh Pittsburgh PA
  • FS Mah
    The Charles T Campbell Laboratory University of Pittsburgh Pittsburgh PA
  • DC Ritterband
    The New York Eye and Ear Infirmary New York NY
  • YJ Gordon
    The Charles T Campbell Laboratory University of Pittsburgh Pittsburgh PA
  • Footnotes
    Commercial Relationships   R.P. Kowalski, None; L.M. Karenchak, None; E.G. Romanowski, None; F.S. Mah, None; D.C. Ritterband, None; Y.J. Gordon, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1585. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      RP Kowalski, LM Karenchak, EG Romanowski, FS Mah, DC Ritterband, YJ Gordon; An In Vitro Comparison of 2nd, 3rd, and 4th Generation Fluoroquinolones Against Bacterial Keratitis Isolates . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1585.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: In the future there will be five topical fluoroquinolones on the market. We compared the in vitro susceptibilities of bacterial keratitis isolates to ciprofloxacin 2nd-gen (C), ofloxacin 2nd-gen (O), levofloxacin 3rd-gen (L), moxifloxacin 4th-gen (M), and gatifloxacin 4th-gen (G). Methods: The MICs (µg/ml) of 177 bacterial keratitis isolates were determined using Etests. The bacterial susceptibilities were determined with the NCCLS standards and were compared statistically along with the potencies (isolates with the lowest MICs). Results:  

Qr, Qs- resistant or susceptible to ciprofloxacin and ofloxacin by disk diffusion. Conclusion: The 4th generation moxifloxacin and gatifloxacin demonstrated increased potency for gram positive bacteria over levofloxacin, ciprofloxacin, and ofloxacin, along with better in vitro susceptibility for isolates that were 2nd and 3rd generation fluoroquinolone-resistant. The 4th generations demonstrated no advantage for gram negative coverage. Clinical studies are needed to confirm our in vitro results.

Keywords: 319 antibiotics/antifungals/antiparasitics • 328 bacterial disease • 449 keratitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×